🇺🇸 FDA
Pipeline program

Namodenoson

CF102-301HCC

Phase 3 small_molecule active

Quick answer

Namodenoson for Hepatocellular Carcinoma is a Phase 3 program (small_molecule) at Can-Fite BioPharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Can-Fite BioPharma
Indication
Hepatocellular Carcinoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials